Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guangmin Li

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Journal of Medicinal Chemistry|September 6, 2014
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineeringThomas H Pillow, Janet Tien, Kathryn L Parsons-Reponte, et al.
Nature Communications|January 11, 2024
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial resultsGail D Lewis, Guangmin Li, Jun Guo, et al.
Journal of Medicinal Chemistry|December 12, 2017
Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease SpecificityBinQing Wei, Janet Gunzner-Toste, Hui Yao, et al.
Molecular Pharmaceutics|July 25, 2018
Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody-Drug ConjugatesZhonghua Pei, Chunjiao Chen, Jinhua Chen, et al.
Chemical Science|April 13, 2022
A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptidesNeelie Zacharias, Vladimir N Podust, Kimberly K Kajihara, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Journal of Medicinal Chemistry|September 6, 2014
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineeringThomas H Pillow, Janet Tien, Kathryn L Parsons-Reponte, et al.
Nature Communications|January 11, 2024
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial resultsGail D Lewis, Guangmin Li, Jun Guo, et al.
Journal of Medicinal Chemistry|December 12, 2017
Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease SpecificityBinQing Wei, Janet Gunzner-Toste, Hui Yao, et al.
Molecular Pharmaceutics|July 25, 2018
Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody-Drug ConjugatesZhonghua Pei, Chunjiao Chen, Jinhua Chen, et al.
Chemical Science|April 13, 2022
A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptidesNeelie Zacharias, Vladimir N Podust, Kimberly K Kajihara, et al.
Pageof 4